Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 286-292

  Gajewski, Thomas F ^a   Fuertes, Mercedes ^a   Spaapen, Robbert ^a   Zheng, Yan ^a   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA CATENIN; BETA INTERFERON; CANCER VACCINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 2; RANTES;

CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; PHENOTYPE; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL MOVEMENT; HUMANS; IMMUNITY, INNATE; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 79953087601     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.11.013     Document Type: Review

References (46)

1. Gajewski T.F., Meng Y., Harlin H. Chemokines expressed in melanoma metastases associated with T cell infiltration. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25:8501.
2. Gajewski T.F., Zha Y., Thurner B., Schuler G. Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol 2009, 27:9002.
3. Louahed J., Gruselle O., Gaulis S., Coche T., Eggermont A.M., Kruit W., Dreno B., Charion Sileni V., Lehmann F., Brichard V.G. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol 2008, 26. (Abstract 9045).
4. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
5. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
6. Harlin H., Kuna T.V., Peterson A.C., Meng Y., Gajewski T.F. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55:1185-1197.
7. Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006, 177:1670-1678.
8. Mortarini R., Piris A., Maurichi A., Molla A., Bersani I., Bono A., Bartoli C., Santinami M., Lombardo C., Ravagnani F., et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003, 63:2535-2545.
9. Dong H., Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003, 81:281-287.
10. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol Med 2004, 10:15-18.
11. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145.
12. Gajewski T.F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007, 13:5256-5261.
13. Mellor A.L., Sivakumar J., Chandler P., Smith K., Molina H., Mao D., Munn D.H. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001, 2:64-68.
14. Nomura T., Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol 2005, 293:287-302.
15. Schwartz R.H. T cell clonal anergy. Curr Opin Immunol 1997, 9:351-357.
16. Brown I.E., Blank C., Kline J., Kacha A.K., Gajewski T.F. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006, 177:4521-4529.
17. Kline J., Brown I.E., Zha Y.Y., Blank C., Strickler J., Wouters H., Zhang L., Gajewski T.F. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008, 14:3156-3167.
18. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
19. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van Den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
20. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
21. Zha Y., Marks R., Ho A.W., Peterson A.C., Janardhan S., Brown I., Praveen K., Stang S., Stone J.C., Gajewski T.F. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006, 7:1166-1173.
22. Olenchock B.A., Guo R., Carpenter J.H., Jordan M., Topham M.K., Koretzky G.A., Zhong X.P. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006, 7:1174-1181.
23. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010, 11:997-1004.
24. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., Latz E., Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
25. Naik E., Dixit V.M. Modulation of inflammasome activity for the treatment of auto-inflammatory disorders. J Clin Immunol 2010, 30:485-490.
26. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
27. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., Calderon B., Schraml B.U., Unanue E.R., Diamond M.S., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100.
28. Massi D., Tarantini F., Franchi A., Paglierani M., Di Serio C., Pellerito S., Leoncini G., Cirino G., Geppetti P., Santucci M. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 2006, 19:246-254.
29. Larue L., Delmas V. The WNT/Beta-catenin pathway in melanoma. Front Biosci 2006, 11:733-742.
30. Messina J.L., Yu H., Riker A.I., Munster P.N., Jove R.L., Daud A.I. Activated stat-3 in melanoma. Cancer Control 2008, 15:196-201.
31. Curtin J.A., Stark M.S., Pinkel D., Hayward N.K., Bastian B.C. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006, 126:1660-1663.
32. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127-1132.
33. Puri N., Ahmed S., Janamanchi V., Tretiakova M., Zumba O., Krausz T., Jagadeeswaran R., Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007, 13:2246-2253.
34. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005, 174:3925-3931.
35. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., Schreiber H., You Z., Kaynor C., Wang X., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007, 179:1960-1968.
36. Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
37. Sznol M., Powderly J.D., Smith D.C., Brahmer J.R., Drake C.G., McDermott D.F., Lawrence D.P., Wolchok J.D., Topalian S.L., Lowy I. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1 BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010, 28:15s. (Abstract 2506).
38. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
39. Rasku M.A., Clem A.L., Telang S., Taft B., Gettings K., Gragg H., Cramer D., Lear S.C., McMasters K.M., Miller D.M., et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6:12.
40. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:99-106.
41. Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14639-14645.
42. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21:233-240.
43. Anichini A., Scarito A., Molla A., Parmiani G., Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J Immunol 2003, 171:2134-2141.
44. Tan J.T., Ernst B., Kieper W.C., LeRoy E., Sprent J., Surh C.D. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002, 195:1523-1532.
45. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
46. Jiang X., Zhou J., Yuen N.K., Corless C.L., Heinrich M.C., Fletcher J.A., Demetri G.D., Widlund H.R., Fisher D.E., Hodi F.S. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008, 14:7726-7732.